Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-380, HER2 inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-380 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-380, HER2 inhibitor; oral | DRUG | Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule. |
Key Inclusion Criteria (Part 1 and Part 2): * Histological or cytological evidence of HER2+ cancer (Part 1) or HER2+ metastatic breast cancer (Part 2). * Patients should have received at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standar...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ARRY-380 is an investigational small molecule being studied for the treatment of cancer, specifically in patients with advanced HER2-positive cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ARRY-380 is a HER2 inhibitor, meaning it targets the HER2 receptor, which is involved in the growth of certain cancer cells. By inhibiting HER2, the drug aims to interfere with cancer cell proliferation in HER2-positive tumors.
Pfizer, Inc. (NYSE: PFE) is the developer of ARRY-380. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced HER2-positive cancer.
ARRY-380 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The drug is still being studied in early-stage clinical trials to assess its safety and tolerability.
ARRY-380 has been studied in one completed Phase 1 clinical trial, NCT00650572, titled "A Study of ARRY-380 in Patients With Advanced HER2+ Cancer." This trial enrolled 50 participants and was conducted in the United States and Canada.